SCHEDULE: Bleichroeder Discloses 6.08% Stake in Cellectar

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have jointly reported a 6.08% beneficial ownership stake in Cellectar Biosciences, Inc., totaling 200,000 common shares.

Summary

• Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach are the reporting persons for this Schedule 13G filing.
• The reporting persons beneficially own 200,000 common shares of Cellectar Biosciences, Inc.
• This ownership represents 6.08% of the company's outstanding common stock.
• The 200,000 shares include 100,000 shares of common stock and 100,000 shares of common stock issuable upon the exercise of warrants.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine ownership disclosure, but the establishment of a significant institutional stake can be viewed as a moderately positive signal of investor confidence in the company.

Positives

• Institutional investor Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has disclosed a significant 6.08% stake in Cellectar Biosciences, Inc., signaling institutional interest.
• The acquisition of shares was stated to be in the ordinary course of business, indicating a long-term investment perspective rather than an activist one.

Future Outlook

The reporting persons acquired and hold the securities in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer. This indicates their intent to remain passive investors.

Management Comments

• Andrew Gundlach certified that, to the best of his knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates a significant institutional investment in Cellectar Biosciences, Inc., a biotechnology company. Such disclosures are common in the biotech sector as institutional investors take positions in companies with promising pipelines or market potential, often signaling confidence in the company's long-term prospects.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide a perception of stability and confidence in the company's stock.
• Company Management: Awareness of a significant institutional shareholder may influence strategic decisions or communication strategies.

Next Steps

• The reporting persons will continue to monitor their investment in Cellectar Biosciences, Inc. and may file amendments to this Schedule 13G as required by changes in their beneficial ownership.

Key Dates

Keywords

Cellectar Biosciences, CLRB, Bleichroeder, Andrew Gundlach, Schedule 13G, beneficial ownership, institutional investment, common shares, warrants